Global Intravenous Immunoglobulin Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Intravenous Immunoglobulin Market 2021 (Includes Business Impact of COVID-19)
Global Intravenous Immunoglobulin Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global Intravenous Immunoglobulin market report has been segmented on the basis of type, application, and region.
Request Covid - 19 Impact
The global Intravenous Immunoglobulin market size was valued at USD $10907.67 million in 2020 and is projected to reach USD $20841.65 million by 2030, and is anticipated to expand at a CAGR of 6.67% over the forecast period from 2020 to 2030.


Global Intravenous Immunoglobulin Market: Overview


Intravenous immunoglobulin (IVIG) is a type of blood product prepared from the serum. IVIGs are sterile products and purified IgG products are manufactured from pooled human plasma. Some of the diseases that intravenous immunoglobulin therapy can treat includes, immune deficiencies like immune thrombocytopenia, Kawasaki disease, lupus, myositis, chronic inflammatory demyelinating polyneuropathy, etc. There are many brands available of IVIG in market. Different brands contain different levels of antibodies in the formulations. IVIG is given generally through an intravenous route of administration. The length of the infusion may depend on the brand used as well as protocol at the hospital or infusion center.


Global Intravenous Immunoglobulin Market: Dynamics


Increasing number of hemophilic patients globally is a key factor and is anticipated to drive growth of the target market over next ten years. In addition, rising prevalence diseases such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, and others. Moreover, increasing geriatric population, rapidly increasing number of various types of neurological disorders and increasing investments in research and development activities of new products development by private as well as government bodies. The aforementioned are some of the other factors expected to boost revenue growth of the global intravenous immunoglobulin market over the forecast period. However, high cost and expense of therapy and stringent health regulations related to IVIG products are the factor expected to restraint revenue growth of the target market to a certain extent.


Global Intravenous Immunoglobulin Market: Segment Analysis


Among the application segments, myasthenia gravis is anticipated to hold for largest market share in terms of revenue. This is primarily attributed to, it is a type of autoimmune disorder of the postsynaptic neuromuscular junction which is characterized by weakness in bulbar, ocular, respiratory muscles, and limb. IVIG for treatment myasthenia gravis aids in destroying and neutralize autoantibodies in the bloodstream and block the production of new autoantibodies.


Global Intravenous Immunoglobulin Market: Trends


The key trends observed in the target market currently are, the established player in the market space is focus on receiving regulatory approval of FDA and thereby expanding its product offering as well as gaining more market share in the global market. In addition, players are adopting for various others extensive growth strategies such as distribution and other collaborative agreements in order to increase its share as well as market penetration into developing countries.


Global Intravenous Immunoglobulin Market: Regional Analysis


In 2018, the markets in North America is anticipated to hold major share in the target market over the forecast period. This is primarily due to, presence of the large plasma production facilities in US and increasing geriatric population that are suffering from various type of chronic diseases. The market in Asia Pacific is anticipated witnessed highest CAGR in terms of revenue growth over the forecoming years. This is primarily due to, growing healthcare spending, rising incidences of immune disorders and diseases, and increasing awareness levels regarding immunoglobulin therapies in countries in the region.


Below are the active patents related to Intravenous Immunoglobulin Market.


Patent Number: US8940877B2

Method to produce an immunoglobulin preparation with improved yield

Abstract

The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Application filed Date:2012-10-16

Application granted Date: 2015-01-27

Current Assignee: Takeda Pharmaceutical Co Ltd

Patent Number: US9241897B2

Immunoglobulin preparation

Abstract

The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Application filed Date: 2011-02-03

Application granted Date: 2016-01-26

Current Assignee: CSL Behring AG

Patent Number: CN102552906B

Productive technology of intravenous injection human immunoglobulin

Abstract

The invention relates to a productive technology of immunoglobulin, in particular relates to a productive technology of intravenous injection human immunoglobulin. The process of extraction and isolation of albumin from blood plasma is mainly carried out by a low temperature ethanol method based on Cohn6 method. The technology comprises the steps of depositing ingredients I+II+III, solving the deposit, regulating the pH value, adding ethanol till the concentration being 13-15%; adding pearlite and kieselguhr after complete depositing, pressurizing, filtering and isolating the deposit produced in the system, taking out the filtration and adding sodium chloride and the ethanol; further adding pearlite and kieselguhr into the mixture solution again, compressing, filtering, isolating, depositing, dissolving the deposit, and adding the ethanol continuously; carrying out depth filtration, afterwards regulating the conductivity and the pH value, carrying out ion exchange chromatography, performing ultrafiltration process, further filtering by using nano-membranes, and adding glycocoll or L-proline. According to the productive technology provided by the invention, the overall yield of human immunoglobulin is improved, the production cost is reduced, the production process is finer and the quality of a product is improved.

Application filed Date:2012-01-11

Application granted Date:2013-11-06

Current Assignee: Xian Hui Tian Blood Products Co Ltd

Global Intravenous Immunoglobulin Market Segmentation:

Segmentation by type:

  
IgG
  
IgA
  
IgM
  
IgE
  
IgD

Segmentation by application:

  
Hypogammaglobulinemia
  
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  
Immunodeficiency Disease
  
Myasthenia Gravis
  
Others (include, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Inflammatory Myopathies, Specific Antibody Deficiency, etc.)


Key Market Players included in the report:


  
ABEONA THERAPEUTICS (US)
  
Baxter international Inc.
  
Bayer Healthcare.
  
BDI Pharma (US)
  
Bio Products Laboratory Limited
  
Biotest AG.(Germany),
  
China Biologic Products Inc. (China)
  
CSL Behring (US)
  
Grifols Inc. (Spain)
  
Kedrion Biopharma Inc.
  
LFB group
  
Octapharma (Switzerland)
  
Shire (Republic of Ireland),
  
Takeda Pharmaceutical Company Limited


Below are the key development related to Intravenous Immunoglobulin Market in 2020 and 2021.


April 2021: ADMA Receives FDA Approval for Increased IVIG Production Scale. Increases plant manufacturing capacity from 400,000L to 600,000L. Source

March 2021: Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. Source

September 2020: European Medicines Agency Approves Label Update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase), Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies. Source